Chemoprevention Trial of Selenium and Prostate Cancer
Annual rept. 1 Apr 2002-31 Mar 2003
ARIZONA UNIV TUCSON
Pagination or Media Count:
The principal purpose of this trial is to assess the potential for the essential nutrient selenium Se to modulate biomarkers of prostate cancer between initial diagnostic biopsy and radical prostatectomy. The scope of work is to randomize at least 110 participants to either a placebo or Se dosages of 200 mug, or 400 mugday. Recruitment is continuing as a result of a no-cost extension. A total of 79 subjects have been randomized. Of these, 72 have completed the study, 6 dropped before completing the study, and 1 is in the process of completing the study.
- Medicine and Medical Research